.jpg)
NSCLC: Racial and Socioeconomic Disparities in Survival Rates
Certain vulnerable groups of patients with metastatic non-small cell lung cancer are in need of more-creative strategies to increase their rates of survival. Read on to learn the details.
Respiratory Sarcopenia: A New Biomarker for Postoperative Outcomes in NSCLC?
Could this physical biomarker—sarcopenia--effectively stratify risk in patients with non-small cell lung cancer?
In Advanced NSCLC, is Concurrent RNA-NGS and DNA-NGS the Best Way?
These investigators compared RNA-NGS plus DNA-NGS with RNA-NGS alone. Using information from various sources permitted analysis of the value of RNA-NGS across diverse settings.